-
Mashup Score: 0Older age, high HBsAg levels linked to increased risk for flare after treatment withdrawal - 11 month(s) ago
Older age, male sex and increased hepatitis B surface antigen correlated with a higher risk for hepatic flare after nucleos(t)ide analogue withdrawal in patients with chronic HBV, according to data at the EASL Congress. “Over the last decades, several studies have shown that stopping new treatment in a selective group of patients may be beneficial since this could result in functional cure,
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 0Racial Disparities in Chronic Hepatitis B: Implications for Treatment and Outcomes - 11 month(s) ago
While African American/Black participants were less likely to meet treatment criteria, treatment receipt did not significantly differ by race, indicating equitable access to treatment.
Source: ContagionLiveCategories: Infectious Disease, Latest HeadlinesTweet-
This observational study of chronic hepatitis B (#HBV) found African American/Black participants were less likely than other races to meet the criteria necessary to initiate HBV treatment. #HealthEquity #Juneteenth https://t.co/OCjNqg0Fke
-
-
Mashup Score: 0Lower diagnostic costs needed for HBV peripartum antiviral prophylaxis to be effective - 11 month(s) ago
The addition of peripartum antiviral prophylaxis to reduce neonatal hepatitis B virus infection could have “substantial extra health benefits,” although decreased diagnostic costs are needed to make this strategy cost-effective.“WHO’s Global Health Sector Strategy on Viral Hepatitis set a target for elimination of mother-to-child transmission of HBV, with the aim to reach
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI from @LancetGastroHep: Lower #diagnostic #costs needed for #HBV peripartum antiviral #prophylaxis to be effective #GITwitter #MedTwitter https://t.co/LIp7GU6f8k
-
-
Mashup Score: 0Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections - 11 month(s) ago
Objective Chronic HBV/HDV infections are a major cause of liver cancer. Current treatments can only rarely eliminate HBV and HDV. Our previously developed preS1-HDAg immunotherapy could induce neutralising antibodies to HBV in vivo and raise HBV/HDV-specific T-cells. Here, we further investigate if a heterologous prime-boost strategy can circumvent T-cell tolerance and preclude HDV superinfection…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet-
#GUTImage from the paper by Burm et al entitled "Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections" via https://t.co/cWeQWeCxaY #HBV #HDV #LiverTwitter https://t.co/VSSO0debsM
-
-
Mashup Score: 0Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections - 11 month(s) ago
Objective Chronic HBV/HDV infections are a major cause of liver cancer. Current treatments can only rarely eliminate HBV and HDV. Our previously developed preS1-HDAg immunotherapy could induce neutralising antibodies to HBV in vivo and raise HBV/HDV-specific T-cells. Here, we further investigate if a heterologous prime-boost strategy can circumvent T-cell tolerance and preclude HDV superinfection…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet-
#GUTImage from the paper by Burm et al entitled "Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections" via https://t.co/cWeQWeCxaY #HBV #HDV #LiverTwitter https://t.co/uBYHazEYky
-
-
Mashup Score: 0Gauging the Influence of Immigration on Hepatitis B in the United States - 12 month(s) ago
Previously estimated 0.32% HBV prevalence in the US is closer to 0.55%, according to new modeling study that accounts for immigrant population.
Source: ContagionLiveCategories: Infectious Disease, Latest HeadlinesTweet-
New modeling analysis accounting for immigrant population increases previously estimated 0.32% #HBV prevalence in US to 0.55% #hepatitis #livertwitter https://t.co/iFz8cw5Nas
-
-
Mashup Score: 0Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections - 12 month(s) ago
Objective Chronic HBV/HDV infections are a major cause of liver cancer. Current treatments can only rarely eliminate HBV and HDV. Our previously developed preS1-HDAg immunotherapy could induce neutralising antibodies to HBV in vivo and raise HBV/HDV-specific T-cells. Here, we further investigate if a heterologous prime-boost strategy can circumvent T-cell tolerance and preclude HDV superinfection…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet-
#GUTImage from the paper by Burm et al entitled "Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections" via https://t.co/cWeQWeCxaY #HBV #HDV #LiverTwitter https://t.co/9tGDmDtGJT
-
-
Mashup Score: 1Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections - 12 month(s) ago
Objective Chronic HBV/HDV infections are a major cause of liver cancer. Current treatments can only rarely eliminate HBV and HDV. Our previously developed preS1-HDAg immunotherapy could induce neutralising antibodies to HBV in vivo and raise HBV/HDV-specific T-cells. Here, we further investigate if a heterologous prime-boost strategy can circumvent T-cell tolerance and preclude HDV superinfection…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet-
#GUTImage from the paper by Burm et al entitled "Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections" via https://t.co/cWeQWeCxaY #HBV #HDV #LiverTwitter https://t.co/J9ldsicfc3
-
-
Mashup Score: 0Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections - 1 year(s) ago
Objective Chronic HBV/HDV infections are a major cause of liver cancer. Current treatments can only rarely eliminate HBV and HDV. Our previously developed preS1-HDAg immunotherapy could induce neutralising antibodies to HBV in vivo and raise HBV/HDV-specific T-cells. Here, we further investigate if a heterologous prime-boost strategy can circumvent T-cell tolerance and preclude HDV superinfection…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet-
#GUTImage from the paper by Burm et al entitled "Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections" via https://t.co/cWeQWeCxaY #HBV #HDV #LiverTwitter https://t.co/jaolgZOy9g
-
-
Mashup Score: 5Researchers team with CDC to expand adult hepatitis B testing - 1 year(s) ago
New CDC recommendation for universal hepatitis B screening could significantly reduce liver cancer in Asians and Black people, researchers say.
Source: ScopeCategories: General Medicine News, Latest HeadlinesTweet-
Did you know that up to 1.6 million people in the U.S. don’t know they’re infected with the hepatitis B virus? Researchers at Stanford Medicine’s Asian Liver Center and Prevention Policy Modeling Lab collaborated to increase screening. #HepatitisB #HBV https://t.co/76jEDrx1bo
-
#Olderage, #malesex and increased #hepatitisBsurfaceantigen correlated with a higher risk for #hepaticflare after nucleos(t)ide analogue withdrawal in #patients with chronic #HBV, Edo Dongelmans, MD of @erasmusuni, said at #EASLCongress https://t.co/QUdMwqAh4f